Fig. 1 · Structure

Documents & Downloads

ACY-1215 (Rocilinostat)

Cat. No. A11940 CAS 1316214-52-4

HDAC6 inhibitor

ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HDAC6 IC50 4.7nM
HDAC2 IC50 48nM
HDAC3 IC50 51nM
HDAC1 IC50 58nM
HDAC8 IC50 100nM
HDAC7 IC50 1.4μM
HDAC5 IC50 5μM
HDAC4 IC50 7μM
HDAC9 IC50 >10μM
HDAC11 IC50 >10μM
Sirtuin1 IC50 >10μM
Sirtuin2 IC50 >10μM

12 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
697 IC50 201 nM Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay [PMID: 31710483]
A2780 IC50 > 5000 nM Cytotoxicity against human A2780 cells after 72 hrs by MTT assay [PMID: 26443078]
A549 IC50 > 5000 nM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 26443078]
A549 IC50 7.7 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 30525585]
HAL-01 IC50 > 25 μM Anticancer activity against human HAL-01 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay [PMID: 34582215]
HAL-01 IC50 2.04 μM Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay [PMID: 36351184]
HCT-116 IC50 > 5000 nM Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay [PMID: 26443078]
HCT-116 IC50 1.85 μM Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay [PMID: 36182802]
HEL IC50 2.54 μM Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay [PMID: 29940115]
HEL IC50 3.75 μM Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay [PMID: 29940115]
HeLa IC50 > 5000 nM Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay [PMID: 26443078]
HepG2 IC50 > 5000 nM Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay [PMID: 26443078]
HL-60 IC50 > 10000 nM Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability for 72 hrs by Celltitre-Glo luminescent assay [PMID: 33360560]
HL-60 IC50 1.54 μM Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay [PMID: 36351184]
HL-60 IC50 10.37 μM Anticancer activity against human HL-60 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay [PMID: 34582215]
HL-60 IC50 2.36 μM Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay [PMID: 30365892]
HL-60 IC50 2.54 μM Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay [PMID: 29940115]
HL-60 IC50 3.75 μM Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay [PMID: 29940115]
HPBALL IC50 6.7 μM Anticancer activity against human HPBALL cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay [PMID: 34582215]
HT-29 IC50 > 5000 nM Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay [PMID: 26443078]

20 records · Scroll to view more

ACY-1215 (Rocilinostat) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of ACY-1215 (Rocilinostat) from 3 published references.

ACY-1215 (Rocilinostat) In Vitro Studies

ACY-1215 (Rocilinostat) was evaluated in an in vitro assay containing acetylated STAT1 and human recombinant HDAC6. Western blotting showed partial restoration of STAT1 acetylation in the presence of HDAC6. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

STAT1 acetylation in the presence of recombinant HDAC6

Biochemical assay · in vitro; acetylated STAT1; human recombinant HDAC6 [1]

In an in vitro assay with acetylated STAT1 and human recombinant HDAC6, ACY-1215 (Rocilinostat) partially restored STAT1 acetylation in the presence of HDAC6, as assessed by western blotting.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
western blot assay to detect STAT1 acetylation level by Acetyl-Lysine antibodyReported result The Acetyl-Lys signal is still weak in the presence of HDAC6 and 1mM inhibitor ACY-1215. 2 mM ACY-1215 partially restored STAT1 acetylation levels by inhibiting HDAC6.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1mM or 2mM
Exposure duration
37 °C for 90 min
Method
added to HDAC6 inhibitor group
Co-treatment
Other interventions in this design: human recombinant HDAC6. Compound effect isolated by the comparison: in the presence of HDAC6.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal models (S8); Materials and methods > In vitro chemical acetylation and enzymatic deacetylation (S64, S65, S66, S68); Results > ACY-1215 down-regulates PD-L1 by promoting STAT1 acetylation (S133, S134, S137); Fig. 1 legend (S150)

western blot assay to detect STAT1 acetylation level by Acetyl-Lysine antibody: western blot assay to detect STAT1 acetylation level by Acetyl-Lysine antibody; comparator: in the presence of HDAC6 — Materials and methods > In vitro chemical acetylation and enzymatic deacetylation (S68); Results > ACY-1215 down-regulates PD-L1 by promoting STAT1 acetylation (S134, S137)

ACY-1215 (Rocilinostat) In Vivo Studies

In SNI-operated male mice, intraperitoneal ACY-1215 (Rocilinostat) ameliorated pain compared with SNI alone, with relatively stable efficacy developing during treatment. A separate comparison with DMSO-treated SNI-operated mice showed reduced p-STAT3 expression following ACY-1215 (Rocilinostat) treatment. In mice injected with SK-N-BE(2) cells, the vehicle-control-versus-ACY-1215 (Rocilinostat) comparison reported fewer lesions in the liver, kidney, adrenal gland, and bone. [2,3]

Mechanical pain responses in mice after SNI surgery

Animal study · male mice; CD-1 mice; SNI-operated mice; n = 8 mice per group [2]

SNI-operated male mice received daily intraperitoneal ACY-1215 (Rocilinostat). Compared with SNI alone, treatment ameliorated SNI-induced pain assessed by von Frey testing, with efficacy becoming relatively stable during treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical thresholds for different groups of male mice in von Frey testsReported result ACY-1215 (20 mg/kg/day): Systemic administration of ACY-1215 ameliorated SNI-induced pain starting from Day 7 post-SNI operation, achieving relatively stable efficacy by Day 13.[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
starting from day 1 post-SNI and continued daily until day 13
Vehicle
10% DMSO in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ACY-1215 (Rocilinostat) 20 mg/kg/dayvehicle (10% DMSO in saline)ACY-1215 (20 mg/kg/day): Systemic administration of ACY-1215 ameliorated SNI-induced pain starting from Day 7 post-SNI operation, achieving relatively stable efficacy by Day 13.[2]
ACY-1215 (Rocilinostat) 20 mg/kg/day
Model: male mice; CD-1 mice; SNI-operated mice; n = 8 mice per group
Methods and source locations

Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Establishment of spared nerve injury (SNI) model (S15); Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90, S94, S95, S97, S99, S100, S102)

Mechanical thresholds for different groups of male mice in von Frey tests: Mechanical thresholds for different groups of male mice in von Frey tests; comparator: vehicle (10% DMSO in saline) — Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S94, S97, S99)

ACY-1215 (Rocilinostat) 20 mg/kg/day · Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90, S94, S97)

Distant organ lesions in mice injected with neuroblastoma cells

Animal study · Mice injected with NB cells via tail vein; SK-N-BE(2) cells; n = 5 mice per group [3]

Mice injected with SK-N-BE(2) cells via the tail vein received daily intraperitoneal ACY-1215 (Rocilinostat) or vehicle. The control-versus-ACY-1215-treated comparison reported fewer lesions in distant organs, including the liver, kidney, adrenal gland, and bone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of metastatic foci in liver and kidney, and incidence of bone metastasisReported result daily intraperitoneal administration of either ACY-1215 (30 mg/kg) or vehicle: fewer lesions in distant organs including the liver, kidney, adrenal gland, and bone[3]

Conditions shared by the study groups

Route
intraperitoneal administration
Treatment course
daily; 4-week endpoint
Vehicle
vehicle
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ACY-1215 (Rocilinostat) 30 mg/kgvehicle (control)daily intraperitoneal administration of either ACY-1215 (30 mg/kg) or vehicle: fewer lesions in distant organs including the liver, kidney, adrenal gland, and bone[3]
ACY-1215 (Rocilinostat) 30 mg/kg
Model: Mice injected with NB cells via tail vein; SK-N-BE(2) cells; n = 5 mice per group
Methods and source locations

Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Metastatic NB Model (S76, S78); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188); Figure 6. legend (S301, S302, S304)

Quantification of metastatic foci in liver and kidney, and incidence of bone metastasis: Quantification of metastatic foci in liver and kidney, and incidence of bone metastasis; comparator: vehicle (control) — Methods > Metastatic NB Model (S76); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188); Figure 6. legend (S304)

ACY-1215 (Rocilinostat) 30 mg/kg · Methods > Metastatic NB Model (S76, S78); Results > Targeting TCF4 Degradation with ACY-1215 Suppressed NB Metastasis (S188)

Phosphorylated STAT3 expression in SNI-operated male mice

Animal study · CD-1 mice; SNI-operated male mice; n = 5 [2]

SNI-operated male mice received intraperitoneal ACY-1215 (Rocilinostat). Treatment reduced p-STAT3 expression compared with SNI-operated mice receiving DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative (Rel.) expression levels of p-STAT3Reported result SNI-operated male mice; ACY-1215 (20 mg/kg/day): Treatment with ACY-1215 reduced p-STAT3 expression.[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
for 14 consecutive days; On the 14th-day post-SNI
Vehicle
10% dimethyl sulfoxide (DMSO)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ACY-1215 (Rocilinostat) 20 mg/kg/daySNI + DMSOSNI-operated male mice; ACY-1215 (20 mg/kg/day): Treatment with ACY-1215 reduced p-STAT3 expression.[2]
ACY-1215 (Rocilinostat) 20 mg/kg/day
Model: CD-1 mice; SNI-operated male mice; n = 5
Methods and source locations

Compound reported in the paper: ACY-1215 (Rocilinostat); Compound label in the paper: ACY-1215

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Chemicals and antibodies (S6); Materials and methods > Establishment of spared nerve injury (SNI) model (S15); Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S112, S114, S116)

Relative (Rel.) expression levels of p-STAT3: Relative (Rel.) expression levels of p-STAT3; comparator: SNI + DMSO — Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S114)

ACY-1215 (Rocilinostat) 20 mg/kg/day · Results > HDAC6 inhibitor ACY-1215 ameliorated neuropathic pain in SNI-operated mice (S90); Results > ACY-1215 increased STAT3 acetylation and decreased its phosphorylation in the spinal cord of SNI-operated mice (S104, S105, S112)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1316214-52-4
Applications HDAC6 inhibitor
Formula C24H27N5O3
Molecular Weight 433.5
Synonyms ACY1215
SMILES
C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 73 mg/mL (168.39 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ACY-1215 (Rocilinostat) Research References

  1. [1] Wen Y, Ye S, Li Z, et al. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy. Cancer Immunol Immunother (2024). PMID: 38231305 DOI: 10.1007/s00262-023-03624-y Source material
  2. [2] Chi Z, Lu B, Liu R, et al. Inhibition of histone deacetylase 6 alleviates neuropathic pain via direct regulating post-translation of spinal STAT3 and decreasing downstream C-C Motif Chemokine Ligand 7 synthesis. J Neuroinflammation (2025). PMID: 40069860 DOI: 10.1186/s12974-025-03400-y Source material
  3. [3] Lou E, Jiang L, Zheng Y, et al. Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation. Neuro Oncol (2026). PMID: 41630015 DOI: 10.1093/neuonc/noag021 Source material

Added to your cart

View Cart Checkout
Loading...